Research programme: extracorporeal anti-cytokine therapy - Advanced BiotherapyAlternative Names: Extracorporeal anti-cytokine therapy research programme - Advanced Biotherapy
Latest Information Update: 04 Nov 2003
At a glance
- Originator Advanced Biotherapy
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 04 Nov 2003 Discontinued for Autoimmune disorders in USA (Extracorporeal)
- 16 Feb 2001 New profile
- 16 Feb 2001 Investigation in Autoimmune disorders in USA (Extracorporeal)